Tyrvaya FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 4, 2021.
FDA Approved: Yes (First approved October 15, 2021)
Brand name: Tyrvaya
Generic name: varenicline
Dosage form: Nasal Spray
Company: Oyster Point Pharma, Inc.
Treatment for: Dry Eye Disease
Tyrvaya (varenicline) is a nasally administered selective cholinergic agonist for the treatment of the signs and symptoms of dry eye disease.
- Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Tyrvaya is thought to work by binding to the cholinergic receptors to activate the trigeminal parasympathetic pathway in the nasal cavity to stimulate natural tear film production.
- Varenicline was first approved in an oral formulation under the brand name Chantix as a treatment for smoking cessation.
- Tyrvaya is administered as one spray in each nostril twice daily (approximately 12 hours apart).
- Common adverse reactions include sneezing, cough, throat irritation, and nose irritation.
Development timeline for Tyrvaya
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
